Related Experiment Video
Updated: Jan 5, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
Negative myoclonus associated with pregabalin
Kwan-Do Park1, Min-Ku Kim1, Se-Jin Lee1
1Department of Neurology, Yeungnam University College of Medicine, Daegu, Korea.
Abstract:
Negative myoclonus (NM) is a jerky, shock-like involuntary movement caused by a sudden, brief interruption of muscle contraction. An 80-year-old man presented with multifocal NM and confusion. Two days before the onset of NM, he commenced the intake of pregabalin at a dose of 150 mg/day for neuropathic pain. His NM resolved completely and mental status improved gradually after the administration of lorazepam intravenously and the discontinuation of pregabalin. Our study suggests that pregabalin can cause NM even in patients without a history of seizures.
Insights
Pregabalin can trigger negative myoclonus (NM), a type of involuntary movement, even in individuals without prior seizure history. Discontinuing the medication and using lorazepam led to symptom resolution in an elderly patient.
Area of Science:
- Neurology
- Pharmacology
Background:
- Negative myoclonus (NM) is characterized by sudden, brief interruptions in muscle contraction, presenting as jerky, shock-like involuntary movements.
- Neuropathic pain management often involves medications like pregabalin.
Observation:
- An 80-year-old male patient developed multifocal NM and confusion.
- The onset of NM occurred two days after initiating pregabalin (150 mg/day) for neuropathic pain.
Findings:
- Intravenous lorazepam administration and discontinuation of pregabalin resulted in complete resolution of NM.
- The patient's mental status gradually improved following these interventions.
Implications:
- This case suggests a potential causal link between pregabalin and negative myoclonus.
- Healthcare providers should consider pregabalin as a potential cause of NM, particularly in patients without a history of seizures.
- Awareness of this adverse effect is crucial for accurate diagnosis and management of involuntary movements in patients taking pregabalin.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...

